A novel approach to addiction: Stephen Hurst, CEO, Savant HWP




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: A novel approach to addiction: Stephen Hurst, CEO, Savant HWP
Released on: May 29, 2014. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    For 2010, the Substance Abuse and Mental Health Services Administration (SAMHSA) estimated that over 22.
  • Summary
  • Transcript
  • Participants
  • Company
For 2010, the Substance Abuse and Mental Health Services Administration (SAMHSA) estimated that over 22.6 million Americans had a chemical substance dependence or abuse problem. The total social and health cost to our society of dealing with alcohol and illegal drug abuse is estimated to exceed $167 billion annually. Nicotine addiction is even more costly; in 2009, the CDC estimated that smokers cost the US $96 billion a year in direct health care costs and an additional $97 billion a year in lost productivity. The total annual cost to the US economy of addiction has been estimated to exceed $500 billion. There are no treatments for craving for either cocaine or methamphetamine addiction. A recent analysis by the National Institute on Drug Abuse (NIDA) estimates the market size for a first-in-class treatment for cocaine addiction at $1.2 billion in annual revenue. Even drugs for smoking addiction, where several drugs are FDA approved, have a one-year abstinence rate of only about 20% as compared to 10% for placebo. Clearly, there is a compelling need for a drug that alleviates substance craving on a long-term basis for all forms of addiction. Considering that no approved drug significantly affects drug craving for any form of addiction, an effective drug would be first-in-class and capture a significant portion of what is currently a multi-billion dollar market. In this interview, filmed at BIO Europe in Turin, Stephen Hurst, CEO of Savant HWP explains to Fintan Walton how they are taking a different approach.
For 2010, the Substance Abuse and Mental Health Services Administration (SAMHSA) estimated that over 22.6 million Americans had a chemical substance dependence or abuse problem. The total social and health cost to our society of dealing with alcohol and illegal drug abuse is estimated to exceed $167 billion annually. Nicotine addiction is even more costly; in 2009, the CDC estimated that smokers cost the US $96 billion a year in direct health care costs and an additional $97 billion a year in lost productivity. The total annual cost to the US economy of addiction has been estimated to exceed $500 billion. There are no treatments for craving for either cocaine or methamphetamine addiction. A recent analysis by the National Institute on Drug Abuse (NIDA) estimates the market size for a first-in-class treatment for cocaine addiction at $1.2 billion in annual revenue. Even drugs for smoking addiction, where several drugs are FDA approved, have a one-year abstinence rate of only about 20% as compared to 10% for placebo. Clearly, there is a compelling need for a drug that alleviates substance craving on a long-term basis for all forms of addiction. Considering that no approved drug significantly affects drug craving for any form of addiction, an effective drug would be first-in-class and capture a significant portion of what is currently a multi-billion dollar market. In this interview, filmed at BIO Europe in Turin, Stephen Hurst, CEO of Savant HWP explains to Fintan Walton how they are taking a different approach.
Stephen Hurst
Savant HWP
Savant HWP
Savant HWP was founded in 2009 to create transformational products in human health, wellness and prevention. Our first products address unmet needs in addiction medicine, where current products are largely ineffective. Addiction results from powerful neurochemical changes in the pleasure centers of the brain. Changes that are not subject to willpower. Addiction is not limited to drugs, alcohol and nicotine. Even food can be just as harmful and, in some ways, more challenging. Addiction affects all of us and our daily lives. Curing addiction requires transformational products that reverse these neurochemical changes, freeing the patient from the uncontrollable desire for the addictive substance or compulsive pleasure-seeking behavior. Current approaches in addiction medicine do not accomplish this. As Savant HWP grows, so will our product offerings with an eye to maximizing patient benefits and value to the people who stand behind the name.